bioAffinity Case Study: 92% Sensitive CyPath Lung Test Spares 71-Year-Old Biopsy
bioAffinity Technologies published a case study on a 71-year-old former heavy smoker whose 7mm pulmonary nodule yielded a negative CyPath® Lung result, enabling a three-month follow-up CT instead of invasive biopsy. The subsequent scan showed nodule resolution, underscoring the test’s reported 92% sensitivity, 87% specificity and potential cost savings.
1. Release of New Clinical Case Study
bioAffinity Technologies released a clinical case study demonstrating the utility of its noninvasive CyPath® Lung test in managing pulmonary nodules in high-risk patients.
2. Patient Profile and Diagnostic Outcome
The subject was a 71-year-old former 20-pack-year smoker with obesity and mild restrictive lung disease whose low-dose CT scan revealed multiple nodules, including a 7mm lesion. CyPath® Lung returned a negative result, allowing a three-month surveillance CT rather than immediate biopsy.
3. CyPath® Lung Performance Metrics
In underlying clinical trials, CyPath® Lung achieved 92% sensitivity, 87% specificity and 88% accuracy for detecting nodules under 20mm by using AI-enhanced flow cytometry analysis of sputum samples.
4. Implications for Clinical Practice and Costs
The case underscores how noninvasive negative results can defer invasive bronchoscopy or biopsy, reduce patient anxiety and lower healthcare costs by avoiding unnecessary procedures in low-risk scenarios.